Long-term follow-up of the COMMAND presented by Gullermo Garcia-Manero at ASH24
Mohamad Mohty, Professor of Hematology at Sorbonne University and head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, reshared a post on X by Uriel Suárez, Resident of hematology at Jiménez Díaz Foundation University Hospital, adding:
“COMMAND is the largest randomized trial in MDS, and now we have long-term follow-up presented by Gullermo Garcia-Manero at ASH24 EPO/ESA clearly needs to retire very quickly.
Luspatercept works in ALL subgroups irrespective of the ring sideroblasts status. The field is finally entering into a modern era.
Luspa is an incredible example on the transfer of scientific discoveries to the bedside (it is a recombinant fusion protein that binds TGF β superfamily ligands to reduce SMAD2 and SMAD3 signaling).”
Quoting Uriel Suárez’s post:
“ASH24. Long-term response analysis of transfusion independence in ESA–naive patients with very low-, low-, or intermediate-risk MDS treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial.”
More posts featuring Mohamad Mohty.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023